Camelot Portfolios’s Sensus Healthcare SRTS Stock Holding History

Camelot Portfolios’s Portfolio SRTS Stock Details SRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-53	Closed	-$281	–	500
2024 Q2	$281	Buy	+53	New	+$244	﹤0.01%	581

Other funds holding SRTS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Camelot Portfolios's SRTS Position: Q3 2024 in Review

Camelot Portfolios sold out of Sensus Healthcare (SRTS) in Q3 2024, closing a stake of 53 shares — an estimated $281 sold.

Camelot Portfolios first reported a position in SRTS in Q2 2024 and held it in 1 quarter. The position peaked at $281 in Q2 2024. 50 funds tracked by Wall St. Rank hold SRTS as of Q3 2024.

Camelot Portfolios reported no remaining Sensus Healthcare position as of Q3 2024 after selling out during the quarter.
Camelot Portfolios sold 53 Sensus Healthcare shares in Q3 2024, an estimated $281.
Camelot Portfolios first reported a position in Sensus Healthcare in Q2 2024 and held it in 1 quarter.
Camelot Portfolios's Sensus Healthcare position peaked at $281 in Q2 2024.
50 funds tracked by Wall St. Rank held Sensus Healthcare as of Q3 2024.

Based on Camelot Portfolios's 13F filing for Q3 2024, filed 12 Nov 2024.